Searchable abstracts of presentations at key conferences in endocrinology

ea0032p296 | Clinical case reports - Thyroid / Others | ECE2013

Parathyroid carcinoma

Adamska Agnieszka , Gorska Maria Zofia

Introduction: Parathyroid carcinoma is a rare endocrine malignancy accounting for <1% of all cases of hyperparathyroidism. Diagnosis and treatment is still difficult.Case report: A 32-year-old women was admitted to the hospital because of mental status changes, polyuria, polydipsia, musculoskeletal pain and weight loss (34 kg during last year). She had history of nephrolithiasis, pancreatitis, cholelithiasis, peptic ulcer disease, osteoporosis and di...

ea0029p796 | Endocrine tumours and neoplasia | ICEECE2012

Pheochromocytoma releasing ACTH: two in one.

Adamska A. , Mysliwiec J. , Gorska M.

Introduction: Ectopic release of ACTH caused by pheochromocytoma is extremely rare. The clinical picture of hypercortisolism is overlapped by catecholamine excess that makes diagnosis more difficult.Case report: A 74-year-old women was admitted to the hospital because of hypertension, recently diagnosed diabetes and weight loss (10 kg per six months). In physical examination: cachexia, dehydratation, pallor, hirsutism, proximal muscle weakness, elevated ...

ea0090rc11.4 | Rapid Communications 11: Late Breaking | ECE2023

Treatment with osilodrostat in ACTH-independent Cushing’s syndrome

Stasiak Magdalena , Adamska Emilia , Lewinski Andrzej

Introduction: Cushing’s disease (CD) is the most common cause of hypercortisolism. Therefore, the majority of studies focused on the efficacy and safety of novel steroidogenesis inhibitors included CD patients only. This is exactly the case with osilodrostat – new potent inhibitor of 11β-hydroxylase. However, approximately 10% of hypercortisolism result from cortisol-secreting adrenal adenoma. Data on potential differences in the treatment with osilodrostat betw...

ea0037ep816 | Pituitary: clinical | ECE2015

Successful treatment of huge pituitary macroadenoma secreting TSH and GH

Adamska Agnieszka , Zapora-Kurel Agnieszka , Gorska Maria

Introduction: The mixed tumor which secretes an excess of both GH and TSH causing acromegaly and hyperthyroidism is rare. The main problem is the late diagnosis, especially in men, even 10 years after the occurrence of the first symptoms.Case report: A 53-year-old men, was admitted to the our department, with complaints of excessive sweating and enlargement of the hands. His medical history included arterial hypertension. Past medical history revealed th...

ea0081p714 | Reproductive and Developmental Endocrinology | ECE2022

Serum concentrations of 17-hydroxyprogesterone and dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their relation to the parameters of glucose metabolism

Stogowska Ewa , Krentowska Anna , Adamska Agnieszka , Lebkowska Agnieszka , Kowalska Irina

Introduction: Polycystic ovary syndrome (PCOS) is characterized by menstrual disorders, hyperandrogenism and polycystic ovaries on ultrasonography. This hormonal disorder is also strongly associated with insulin resistance. The diagnosis of PCOS can be established after the exclusion of other causes of mentioned symptoms, such as non-classic congenital adrenal hyperplasia (NCAH). To date, several studies suggest the increased serum concentration of 17-hydroxyprogesterone (17-O...

ea0035p1028 | Thyroid (non-cancer) | ECE2014

The role of peroxisome proliferator-activated receptors α polymorphisms in Graves' disease and orbitopathy

Janusz Przemyslaw , Pawlak-Adamska Edyta , Bolanowski Marek , Daroszewski Jacek

Understanding the genetic etiology of Graves’ disease (GD) and Graves’ orbitopathy (GO) is recognized as an urgent priority. Since peroxisome proliferator-activated receptors α (PPARα) exhibit anti-inflammatory and immunomodulatory activity, and are required for the control of the adipose inflammation process their role in the GD and GO pathogenesis has been proposed. Abnormal expression and/or function of PPARα could suppress the inflammatory response...

ea0029p1590 | Thyroid (non-cancer) | ICEECE2012

Polymorphism of the PPAR-γ2 gene and Graves’ orbitopathy: the Ala variant confers decreased risk of eye symptoms

Daroszewski J. , Pawlak-Adamska E. , Bolanowski M. , Frydecka I.

Introduction: Peroxisome proliferatior-activated receptor-γ2 (PPAR-γ2) plays a crucial role in adipogenesis and has been shown to be involved in the control of immunoregulation and inflammation. Orbital fibroblast differentiation to adipocytes is a PPAR-γ dependent process essential for pathogenic tissue remodeling in Graves’ orbitopathy (GO). Genetic variation in PPAR-γ2 gene may modulate expression and/or function of molecule encoded by this gene.</p...

ea0026p389 | Thyroid (non cancer) | ECE2011

The CT60 and Jo31 polymorphisms of CTLA-4 gene are associated with disease progression in Graves’ disease

Daroszewski J , Pawlak-Adamska E , Bolanowski M , Frydecka I

Introduction: Both genetic and environmental factors contribute to clinical manifestation of Graves’ disease including the response to medical therapy. CTLA-4 gene is an important inhibitor of T-cell activation and its polymorphisms may influence the course of the disease.Goal: We investigated the association between CTLA−4 gene polymorphisms: c.49A>G, g.319C>T, g.*642AT(8_33), CT60, and Jo31 and the response to ph...

ea0020p278 | Clinical case reports and clinical reports | ECE2009

Cushing syndrome caused by topical corticosteroids coexistent with pituitary incidentaloma – case report

Karczewska-Kupczewska Monika , Adamska Agnieszka , Kowalska Irina , Gorska Maria

Iatrogenic Cushing syndrome caused by the use of steroid medications is common because of the widespread use of these medications for the treatment of many diseases, however development of Cushing syndrome from the topical corticosteroids is very rare in adults.A 45-year-old men (BMI: 44 kg/m2), with a history of psoriasis, developed manifestations of Cushing syndrome, which included weight gain, central obesity, moon face, facial plethora, bu...

ea0041ep683 | Female Reproduction | ECE2016

Increased level of serum irisin concentration and its regulation by hyperinsulinemia in women with polycystic ovary syndrome

Adamska Agnieszka , Karczewska-Kupczewska Monika , Lebkowska Adamska , Milewski Robert , Gorska Maria , Otziomek Elzbieta , Nikolajuk Agnieszka , Wolczynski Slawomir , Straczkowski Marek , Kowalska Irina

Background: Irisin is an adipokine/myokine which could be connected with insulin sensitivity. Polycystic ovary syndrome (PCOS) is characterized by oligo- or anovulation, polycystic ovary, hyperandrogenism and insulin resistance.Objective: The aim of the present study was to determine the relationship between serum irisin concentration and insulin sensitivity (Mffm) as well as the effect of insulin infusion on circulating irisin levels in PCOS ...